Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.
[Blood Advances]
7992332
{7992332:BBBBBBBB}
apa
50
1
167861
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
